A Study to Examine Changes in GIP Plasma Levels Following Gastric Bypass Surgery in Obese Patients
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00207389 |
Recruitment Status :
Terminated
(Insufficient funding)
First Posted : September 21, 2005
Last Update Posted : January 26, 2017
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease |
---|
Obesity Type 2 Diabetes Mellitus Insulin Resistance |

Study Type : | Observational |
Actual Enrollment : | 5 participants |
Observational Model: | Cohort |
Time Perspective: | Prospective |
Official Title: | A Pilot Study to Examine the Relationship Between Changes in Plasma GIP Levels and Other Gastrointestinal Peptides Following Gastric Bypass Surgery in Obese Patients |
Study Start Date : | March 2004 |
Actual Primary Completion Date : | August 2006 |
Actual Study Completion Date : | August 2006 |

Group/Cohort |
---|
Laparoscopic gastric bypass
Patients undergoing Laparoscopic gastric bypass
|
Open gastric bypass
Patients undergoing Open gastric bypass
|
- GIP area under the curve after OGTT
- Other GI peptides and hormones after OGTT

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 21 Years to 64 Years (Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Patients 21-64 years of age
- Obese (defined as a body mass index, BMI, > or = 30)
- Type 2 diabetes or impaired glucose tolerance
- Have been selected and scheduled for gastric bypass surgery.
Exclusion Criteria:
- Substance abuse
- Consumption of more than two alcoholic drinks per day
- Use of more than 20 units of insulin (any brand or type) per day
- Fasting blood glucose >180mg/dl on screening bloodwork.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00207389
United States, Massachusetts | |
Boston University Medical Center | |
Boston, Massachusetts, United States, 02118 |
Principal Investigator: | Caroline Apovian, MD | Boston University Medical Cneter | |
Principal Investigator: | Michael Wolfe, MD | Boston University | |
Study Chair: | Marie Mcdonnell, MD | Boston University | |
Study Chair: | Harmony Allison, MD | Boston University |
Responsible Party: | Caroline Apovian, Principal Investigator, Boston Medical Center |
ClinicalTrials.gov Identifier: | NCT00207389 |
Other Study ID Numbers: |
H-22610 |
First Posted: | September 21, 2005 Key Record Dates |
Last Update Posted: | January 26, 2017 |
Last Verified: | January 2017 |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
Incretins:GIP , GLP-1 Gastric bypass surgery Laparoscopic gastric bypass surgery Postprandial expression of GIP |
Diabetes Mellitus, Type 2 Insulin Resistance Diabetes Mellitus Glucose Metabolism Disorders |
Metabolic Diseases Endocrine System Diseases Hyperinsulinism |